BCM
FATE icon

Bayesian Capital Management’s Fate Therapeutics FATE Stock Holding History

Bayesian Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17,174
Closed -$60.1K – 782
2024
Q3 		$60.1K Buy
+17,174
New +$66.8K 0.01% 620
2024
Q2 		– Sell
-39,800
Closed -$292K – 856
2024
Q1 		$292K Buy
39,800
+20,164
+103% +$125K 0.03% 557
2023
Q4 		$73.4K Sell
19,636
-18,600
-49% -$43.9K 0.01% 670
2023
Q3 		$81.1K Sell
38,236
-22,000
-37% -$72.9K 0.01% 622
2023
Q2 		$287K Buy
60,236
+31,900
+113% +$176K 0.03% 551
2023
Q1 		$162K Buy
28,336
+9,600
+51% +$57.9K 0.02% 636
2022
Q4 		$189K Buy
18,736
+3,900
+26% +$73.2K 0.03% 610
2022
Q3 		$332K Buy
+14,836
New +$429K 0.07% 385
2021
Q2 		– Sell
-6,300
Closed -$519K – 480
2021
Q1 		$519K Buy
+6,300
New +$604K 0.12% 223

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bayesian Capital Management's FATE Position: Q4 2024 in Review

Bayesian Capital Management sold out of Fate Therapeutics (FATE) in Q4 2024, closing a stake of 17,174 shares — an estimated $60.1K sold.

Bayesian Capital Management first reported a position in FATE in Q1 2021 and held it in 9 quarters. The position peaked at $519K in Q1 2021. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2024.

  • Bayesian Capital Management reported no remaining Fate Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 17,174 Fate Therapeutics shares in Q4 2024, an estimated $60.1K.
  • Bayesian Capital Management first reported a position in Fate Therapeutics in Q1 2021 and held it in 9 quarters.
  • Bayesian Capital Management's Fate Therapeutics position peaked at $519K in Q1 2021.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2024.

Based on Bayesian Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.